The Innovation Gateway

The Innovation Gateway is a new high-quality incubator space for life-science companies, at the heart of The London Cancer Hub in Sutton, South London – a partnership led by The Institute of Cancer Research and the London Borough of Sutton.

The Innovation Gateway represents a major step forward in realising The London Cancer Hub’s vision of becoming the world’s leading district for cancer research, treatment and commercial enterprise.

CumbrianHouse-EntranceView(A4)-FINAL-sml

Facilities on site

At Sutton, the Innovation Gateway offers state-of-the-art laboratory equipment, offices and other facilities to a wide range of companies in the life sciences – including potentially the ICR’s new £75m Centre for Cancer Drug Discovery, which is only metres away.

The site contains around 6,300 square feet of space, of which about 3,500 square feet is set to be new laboratories.

Partnerships and collaborations

Occupiers of the Innovation Gateway will also have opportunities to collaborate with world-leading academic researchers at the ICR. We are already one of the top academic institutions in the world in partnering with industry, currently working with more than 100 companies – from small biotech and medtech firms to big pharma.

In collaboration with The Royal Marsden NHS Foundation Trust, we also run one of the world’s largest and most successful centres for phase I clinical trials – leading around 50 early-stage trials of novel drugs at any one time, with many in collaboration with industry.

Read the latest Innovation Gateway news

Red, yellow and blue microscope image of immunofluorescence staining showing extension of prostatic adenocarcinoma into the bladder wall
New drug hope for prostate cancer patients

10/01/25

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical Cancer Research.
See full story
Left: Plates showing the impact of olaparib on BRCA cancer cells and minimal impact of on healthy cells. (Right) Lynparza, olaparib's brand name, drug packaging. Photo credit: Science Museum Group
ICR welcomes NICE recommendation of olaparib for advanced breast cancer

09/01/25

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.
See full story
Scientists in the lab pipetting
Supporting scientists to choose the best chemical probes

02/01/25

A ‘TripAdvisor-style’ website that helps scientists choose the best small-molecule tools for their experiments has been greatly expanded to include expert reviews of hundreds of chemical probes that can be used to increase the robustness of fundamental and applied research and help develop an arsenal of new cancer drugs.
See full story
Sentinal leadership team Georgia Mitsi, Chris Bakal, Matt de Vries
Precision oncology company Sentinal4D completes pre-seed funding round and launches to the public

20/12/24

Sentinal4D, a spinout company from The Institute of Cancer Research, London, has been announced to the public – having closed of its first round of funding and appointed its foundational leadership team.
See full story
ICR Carol service ceremony view of overhead in the chapel
Stars bring Christmas cheer to Carols from Chelsea

18/12/24 - Mernie Gilmore

Christmas arrived in style as celebrities and guests got into the festive spirit at Carols from Chelsea – raising more than £125,000 for The Institute of Cancer Research, London
See full story
breast cancer cell
Major trial shows prolonged benefit of olaparib in early-stage inherited breast cancer

12/12/24

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
See full story
Breast cancer cell spheroid blue and purple
New understanding of aggressive form of breast cancer paves the way for tests and treatments

10/12/24

Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.
See full story
Breast cancer cell
Scientific achievements of 2024

02/12/24

We've selected a range of discoveries from 2023/24 – chosen because they illustrate the quality and breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.
See full story
Johann de Bono and Mateus Crespo Prostate cancer cells 547x410
Scientists can predict how long prostate cancer patients will respond to olaparib

21/11/24

Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP inhibitor drug, olaparib, according to new research published in the journal Cancer Cell.
See full story
NovaSeq genome sequencing machine
New potential cancer-driving genes unveiled, opening new paths for precision treatments

19/11/24

Researchers have carried out an in-depth analysis of 10,478 cancer genomes across 35 different cancer types, identifying 330 potential cancer-driving genes, 74 of which are newly associated with cancer. The findings highlight the potential to develop new, more targeted treatment options for cancer patients.
See full story
Blue man van offering free health checks to men
Mobile ‘Man Van’ spots prostate cancer more quickly and cheaply than via GPs

16/11/24

Mobile testing ‘Man Van’ can diagnose prostate cancer in at-risk groups earlier and more affordably than GPs, according to new research.
See full story
New treatment target for aggressive leukaemia discovered by disrupting its genome organisation

12/11/24

Researchers have identified a key weakness in acute myeloid leukaemia, offering a promising new strategy to delay the progression of this aggressive blood cancer. The discovery focuses on disrupting the function of a certain protein complex that cancer cells, including leukaemia cells, rely on to maintain their abnormal growth.
See full story
Metastatic breast cancer cells in pleural fluid
Powerful new therapy doubles progression-free survival in advanced breast cancer

30/10/24

A three-drug combination for aggressive advanced breast cancer doubles the length of time before the cancer progresses, compared with a drug combination currently available on the NHS, new research has shown.
See full story
More than £5 million secured for the ICR from Cancer Research UK’s RadNet programme to fund work in radiotherapy

30/10/24

Cancer Research UK (CRUK) has awarded The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust a substantial £5.14 million through its radiation research network (RadNet) to support pioneering research in radiation therapy.
See full story
PET scans of a glioblastoma patient's brain, 72 hours after injection with the radiotracer.
New imaging technique could spot patients with aggressive brain tumours who would benefit from immunotherapy

24/10/24

A new imaging technique could mean patients with aggressive glioblastomas benefit from cutting edge immunotherapy treatments, according to researchers.
See full story
World's first trial to test multiple treatments for brain cancers

23/10/24

A pioneering research study which will allow brain cancer patients to access drugs that are precisely targeted to their disease and swap to different treatments if needed, has launched in the UK.
See full story
Blood samples in tubes
£1.5m AI and genetics project to find men with deadliest prostate cancers early

19/10/24

Doctors could predict whether a man’s prostate cancer will be aggressive at the point of diagnosis – giving him the best targeted treatment quickly before it spreads – thanks to a new £1.5 million research project harnessing artificial intelligence and cutting-edge genetic analysis.
See full story
Nurse and patient on bed
New drug combination offers hope to women with rare treatment-resistant ovarian cancer

17/10/24

A combination of two drugs which can block the growth of cancer cells has shown promising results in women with a form of ovarian cancer that rarely responds to chemotherapy or hormone therapy.
See full story
Cyberknife
Higher doses of radiotherapy cuts treatment time by 75% in localised prostate cancer patients, while maintaining high cure rates

16/10/24

People with intermediate risk, localised prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, according to researchers from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust.
See full story
The container to collect saliva in at home
Prostate cancer spit test could save the NHS £500 million a year

13/10/24

Thousands of men could have their prostate cancer diagnosed at an earlier stage when it is easier and cheaper to treat, thanks to a new spit test which can be taken at home.
See full story
Innovation Gateway pic inside

Preview tour

Take a 360 degree virtual tour around the Innovation Gateway and see the laboratories, office spaces and other facilities.
Take a look inside
news image png

Latest news

Keep yourself updated with all the latest news stories, blogs and other features about the Innovation Gateway on The London Cancer Hub website.

Read more
Innovation Gateway at The London Cancer Hub

Brochure

Read the Innovation Gateway brochure to learn more about its facilities, opportunities for collaboration and plans for the future.

Download the brochure

Opportunity: Antibody-derived small molecules and ‘macrodrug’ degraders

Commissioner: Professor Terence Rabbitts

More details & apply...

Opportunity: A small molecule drug conjugate as a novel prodrug-activating platform

Commissioner: Professor Udai Banerji

More details & apply...